JCR Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
JCR Pharmaceuticals has been growing earnings at an average annual rate of 7.7%, while the Pharmaceuticals industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 11.7% per year. JCR Pharmaceuticals's return on equity is 7.4%, and it has net margins of 10.2%.
Key information
7.7%
Earnings growth rate
7.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 11.7% |
| Return on equity | 7.4% |
| Net Margin | 10.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00
Aug 09
Earnings Miss: JCR Pharmaceuticals Co., Ltd. Missed EPS By 90% And Analysts Are Revising Their Forecasts
Aug 03JCR Pharmaceuticals (TSE:4552) Will Pay A Dividend Of ¥10.00
Jul 26JCR Pharmaceuticals (TSE:4552) Is Paying Out A Dividend Of ¥10.00
Jul 12JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
May 22JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00
Mar 18JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00
Feb 29Revenue & Expenses Breakdown
How JCR Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 40,208 | 4,098 | 24,708 | 0 |
| 31 Mar 24 | 42,871 | 5,507 | 12,485 | 11,234 |
| 31 Dec 23 | 41,365 | 5,364 | 14,321 | 8,802 |
| 30 Sep 23 | 43,034 | 8,063 | 13,172 | 8,802 |
| 30 Jun 23 | 35,545 | 4,014 | 11,921 | 8,802 |
| 31 Mar 23 | 34,343 | 3,772 | 11,678 | 8,802 |
| 31 Dec 22 | 37,508 | 5,154 | 13,267 | 7,175 |
| 30 Sep 22 | 38,280 | 6,235 | 13,252 | 7,175 |
| 30 Jun 22 | 50,875 | 14,343 | 13,943 | 7,175 |
| 31 Mar 22 | 51,082 | 14,507 | 13,511 | 7,175 |
| 31 Dec 21 | 50,931 | 16,549 | 14,071 | 5,360 |
| 30 Sep 21 | 47,517 | 14,899 | 12,771 | 5,360 |
| 30 Jun 21 | 34,717 | 7,657 | 10,483 | 5,360 |
| 31 Mar 21 | 30,085 | 6,892 | 8,624 | 5,360 |
| 31 Dec 20 | 26,128 | 4,137 | 7,243 | 5,997 |
| 30 Sep 20 | 24,496 | 2,983 | 6,685 | 5,997 |
| 30 Jun 20 | 24,807 | 3,076 | 7,396 | 5,997 |
| 31 Mar 20 | 24,781 | 2,678 | 7,638 | 5,997 |
| 31 Dec 19 | 25,709 | 3,653 | 8,909 | 4,354 |
| 30 Sep 19 | 24,121 | 3,260 | 9,000 | 4,354 |
| 30 Jun 19 | 23,638 | 3,802 | 7,802 | 4,354 |
| 31 Mar 19 | 23,160 | 3,715 | 7,271 | 4,354 |
| 31 Dec 18 | 20,874 | 2,454 | 7,177 | 4,211 |
| 30 Sep 18 | 20,682 | 2,566 | 6,745 | 4,211 |
| 30 Jun 18 | 20,885 | 2,857 | 6,642 | 4,211 |
| 31 Mar 18 | 20,594 | 3,070 | 6,470 | 4,211 |
| 31 Dec 17 | 20,233 | 2,930 | 6,502 | 4,071 |
| 30 Sep 17 | 19,738 | 2,722 | 6,387 | 4,071 |
| 30 Jun 17 | 18,670 | 2,079 | 6,095 | 4,071 |
| 31 Mar 17 | 18,085 | 1,863 | 5,920 | 4,071 |
| 31 Dec 16 | 17,483 | 1,668 | 6,061 | 3,348 |
| 30 Sep 16 | 17,190 | 1,751 | 5,511 | 3,348 |
| 30 Jun 16 | 17,091 | 1,620 | 5,618 | 3,348 |
| 31 Mar 16 | 17,438 | 1,789 | 5,478 | 3,348 |
| 31 Dec 15 | 17,594 | 2,299 | 5,383 | 3,334 |
| 30 Sep 15 | 17,482 | 2,281 | 5,405 | 3,334 |
| 30 Jun 15 | 17,192 | 1,861 | 5,678 | 3,334 |
| 31 Mar 15 | 16,855 | 1,682 | 5,713 | 3,334 |
| 31 Dec 14 | 16,380 | 1,066 | 6,792 | 2,202 |
| 30 Sep 14 | 16,516 | 1,319 | 6,895 | 2,202 |
| 30 Jun 14 | 16,117 | 1,316 | 6,280 | 2,202 |
| 31 Mar 14 | 15,705 | 1,296 | 6,116 | 2,202 |
| 31 Dec 13 | 15,669 | 1,517 | 6,269 | 1,991 |
| 30 Sep 13 | 14,818 | 958 | 6,150 | 1,991 |
Quality Earnings: 4552 has high quality earnings.
Growing Profit Margin: 4552's current net profit margins (10.2%) are lower than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4552's earnings have grown by 7.7% per year over the past 5 years.
Accelerating Growth: 4552's earnings growth over the past year (2.1%) is below its 5-year average (7.7% per year).
Earnings vs Industry: 4552 earnings growth over the past year (2.1%) did not outperform the Pharmaceuticals industry 8.6%.
Return on Equity
High ROE: 4552's Return on Equity (7.4%) is considered low.